SpringWorks Therapeutics
SWTX
Market cap $3.52B

46.78 USD

+0.02

0.04%

At close Jun 13, 4:00 PM EDT

After hours

46.78

+0.00

0.00%

1 day

0.04%

5 days

-0.06%

1 month

1.21%

3 months

-6.01%

6 months

22.14%

Year to date

29.66%

1 year

19.52%

5 years

5.36%

10 years

106.72%

About: SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

Employees: 368

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

387% more first-time investments, than exits

New positions opened: 112 | Existing positions closed: 23

141% more call options, than puts

Call options by funds: $287M | Put options by funds: $119M

40% more funds holding

Funds holding: 215 [Q4 2024] → 302 (+87) [Q1 2025]

29% more funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 9 (+2) [Q1 2025]

11% more capital invested

Capital invested by funds: $2.92B [Q4 2024] → $3.25B (+$324M) [Q1 2025]

5% less repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 86

10.62% less ownership

Funds ownership: 108.72% [Q4 2024] → 98.1% (-10.62%) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$47

0%

upside

Avg. target

$47

0%

upside

High target

$47

0%

upside

4 analyst ratings

0 positive

0%

4 neutral

100%

0 negative

0%

Guggenheim Michael Schmidt	0%upside $47	Neutral Reiterated	12 May 2025
HC Wainwright & Co. Robert Burns	0%upside $47	Neutral Downgraded	30 Apr 2025
TD Cowen Yaron Werber	0%upside $47	Hold Downgraded	29 Apr 2025
Barclays Peter Lawson	0%upside $47	Equal-Weight Downgraded	28 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about SWTX published over the past 30 days

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of SpringWorks will receive $47.00 in cash for each share of SpringWorks that they own. KSF is seeking to determine whether this consideration and the pro.

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

Zacks Investment Research

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

Zacks Investment Research

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago.

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of SpringWorks will receive $47.00 in cash for each share of SpringWorks that they own. KSF is seeking to determine whether this consideration and the pro.

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

Zacks Investment Research

Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in SpringWorks Therapeutics (SWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX

NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX ), relating to the proposed merger with Merck KGaA, Darmstadt, Germany.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) and its board of directors concerning the proposed acquisition of the company by Merck KGaA. Stockholders will receive $47.00 for each share of SpringWorks Therapeutics stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of SpringWorks will receive only $47 per share in cash, which represents an equity value of.

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics (SWTX) for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments.

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

See News Rankings

Charts implemented using Lightweight Charts™